My primary research focus is on the role of aging and aging-related conditions in hereditary bleeding disorders, specifically von Willebrand disease and hemophilia. My current research interests focus on the effects of aging on von Willebrand factor levels and bleeding phenotype in von Willebrand disease.
My clinical interests involve non-cancerous blood disorders, specifically disorders of hemostasis and thrombosis, including von Willebrand disease and hemophilia. At the Hemophilia Center of Western Pennsylvania, my clinic consists of patients with bleeding or clotting disorders. In addition, I have a general benign hematology clinic at Falk Medical Building.
- BS, West Virginia University, 2004
- MD, Marshall University, 2008
- MS, University of Pittsburgh, 2015
- Residency, Internal Medicine, University of Pittsburgh Medical Center, 2011
- Fellowship, Hematology/Oncology, University of Pittsburgh Medical Center, 2014
Education & Training
Seaman C. Efficacy of adjusted weight-based dosing of DDAVP in type 1 von Willebrand disease. Blood Coagulation and Fibrinolysis. 2023; 34: 462-464.
Seaman C. Von Willebrand disease in older patients: A retrospective electronic health record review. Clinical Applied Thrombosis/Hemostasis. 2022; 28: 1-6.
Seaman C, Yabes J, Lalama C, Ragni MV. Factor VIII concentrate dosing with alternative descriptors of body weight in overweight and obesity: A randomized, controlled, open-label, crossover trial. Haemophilia. 2021; 27: 351-357.
Seaman C, Bertolet M, Zhang J, Ragni MV. Quality of peri-procedural care in patients with von Willebrand disease. Haemophilia. 2021; 27: 830-836.
Seaman C, Ragni MV. The effects of age on von Willebrand factor and bleeding symptoms in von Willebrand disease. Thrombosis Haemostasis. 2020; 120: 1159-1169.
Seaman C, Ragni MV. Perioperative management of von Willebrand disease: An institutional experience. Haemophilia. 2019; 25: 199-203.
Seaman C, Ragni MV. The association of aging with von Willebrand factor levels and bleeding risk in type 1 von Willebrand disease. Clinical and Applied Thrombosis/Hemostasis. 2018; 24: 434-438.
Apostolova MH, Seaman C, Comer DM, Yabes YG, Ragni MV. Prevalence and risk factors associated with hypertension in von Willebrand disease. Clinical and Applied Thrombosis/Hemostasis. 2018; 24: 93-99.
Seaman C, George KM, Ragni M, Folsom AR. Association of von Willebrand factor deficiency with prevalent cardiovascular disease and asymptomatic carotid atherosclerosis: The Atherosclerosis Risk in Communities Study. Thrombosis Research. 2016; 236-238
Seaman C, Yabes J, Comer D, Ragni MV. Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge. Journal of Thrombosis and Haemostasis. 2015; 13: 1999-2013.
- National Institutes of Health loan repayment plan award, 2019-2023
- Member, Executive Committee, Mid-Atlantic Region III Federally Funded Hemophilia Treatment Center, 2020-present
- Member, Early Career Reviewer, Center for Scientific Review, NIH, 2021-present
- Member, K Awardee to R Advancement Training Leadership Council (KARAT), University of Pittsburgh, 2021-present
- Ad Hoc Reviewer, Hemostasis, Thrombosis, Bloods Cells and Transfusion Study Section, NIH, 2022
- Member, HONORS Study Section, American Society of Hematology, 2022-present
- Member, Ambassador Program, American Society of Hematology, 2022-2023
- Member, Presentation and Publication Committee, Community Counts: CDC Public Health Surveillance Project for Bleeding Disorders, 2018-2021
- Member, Expert Contributor, British Medicine Journal: Best Practice, Von Willebrand disease, 2023-present
